High-throughput and automation are the keywords in any cancer diagnostic lab – our Xmatrx® series are just that and more! Xmatrx Elite is versatile for any slide-based staining – IHC, ISH, FISH, multiplex IHC, in situ PCR, micro-RNA, and special staining (SS). Crisp and reliable staining result! Everytime!
As we step into the era of personalized medicine, we need to characterize and validate novel cancer targets precisely – not just for therapeutic purpose but as diagnostic biomarkers. The tumor is no longer just diagnosed by morphology but by immunohistochemistry and other molecular patterns – in a multiplex and high-throughput technology platform. Cancer biomarkers are of different kinds ranging from DNA, RNA, RNAi, and protein. Amongst the protein markers, there are immune molecules (ligands or surface receptors) that are expressed specifically in a cancer context, either in pre-cancerous cells or cancerous cells or in combative immune cells (1).
The Synaptophysin (SYN) gene is located on the short arm of the X chromosome. Mutations in this gene are associated with X-linked mental retardation (XLMR). The SYN gene product is a 38 kD glycoprotein that is localized to the membrane of synaptic vesicles. Using immunohistochemistry, synaptophysin can be identified in a range of neural and neuroendocrine tissues, including neurons of the central nervous system, cells of the adrenal medulla, thyroid and pancreatic islets. As a specific marker for these tissues, it can be used to identify tumors originating from them, such as neuroblastoma, retinoblastoma, phaeochromocytoma, carcinoid, small-cell carcinoma, medulloblastoma and medullary thyroid carcinoma.
May 12, 2016
Colon cancer is the third most commonly diagnosed cancer and the second leading cause of cancer death in men and women combined in the United States. In 2016 about 140,000 people will be diagnosed and 50,000 will die from this disease. On average, the lifetime risk of developing colon cancer is about 5%, however, this varies widely according to individual risk factors. About 72% of cases arise in the colon and about 28% in the rectum. In recent years, introduction of a new adjuvant chemotherapy for patients with stage III colon cancer, was very successful and significantly increased disease-free survival in these patients. However, there was no improvement in disease-free survival for patients with earlier-stage (stage I and II) disease due to the lack of simple, reliable criteria for the identification of patients who are at high risk for relapse. Now, a groundbreaking study published in the New England Journal of Medicine, demonstrated that CDX2 antibodies from BioGenex (Clone CDX2-88) can be employed in a new prognostic approach and help save lives of stage II Colon Cancer patients.
Apr 21, 2016
Urothelial Carcinoma (UCC, also known as transitional cell carcinoma) is a cancer that starts in the urothelial cells, which line the inside of the bladder and other parts of the urinary tract. According to the American Cancer Society there were over 76,000 new cases of bladder cancer diagnosed and over 15,000 deaths from advanced bladder cancer in the United States in 2014. At stage I, the 5-year survival rate is about 88% but at stage IV, the 5-year survival rate falls to 15%. Poor prognosis and ineffective therapies for patients with advanced bladder cancer make the discovery of new drugs very important for the treatment of this common disease.
In a pioneering study published last month in Molecular Cancer Therapeutics, researchers at Agensys Inc. identified the SLITRK6 protein as a new UCC biomarker and developed a novel antibody-drug conjugate (ADC) targeting SLITRK6 for the treatment of metastatic bladder cancer. Recent advances in the antibody-drug conjugate (ADC) technology and two recently approved ADCs have brought this drug class to the forefront of drug development in oncology.
Mar 22, 2016
The incidence of melanoma, the most deadly form of skin cancer, has doubled in the past 40 years. Globally, in 2012, melanoma occurred in 232,000 people and resulted in 55,000 deaths. In 2016, it is estimated that there will be 76,380 new cases of melanoma in the United States and 10,130 deaths from the disease. If melanoma is diagnosed and treated early, it is typically curable, but if it is not, melanoma becomes hard to treat and is often fatal.